U.S. Markets close in 4 hrs 33 mins

UCB SA (UCB.BR)

Brussels Stock Exchange - Brussels Stock Exchange Delayed Price. Currency in EUR
Add to watchlist
57.55+0.45 (+0.79%)
As of 5:12PM CEST. Market open.

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
http://www.ucb-group.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7,500

Key Executives

NameTitlePayExercisedAge
Mr. Jean-Christophe TellierChief Exec. Officer and Exec. Director3.07MN/A58
Mr. Detlef ThielgenChief Financial Officer and Exec. VPN/AN/A57
Dr. Ismail Kola Ph.D.Chief Scientific Officer & New Medicines Patient Value Unit HeadN/AN/A60
Ms. Anna S. RichoExec. VP and Gen. CounselN/AN/A57
Dr. Bharat TewarieChief Marketing Officer and Exec. VPN/AN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy. Its product pipeline includes UCB0942 for highly drug resistant epilepsy; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab for various indications; bimekizumab, add-on to Cimzia for rheumatoid arthritis; seletalisib for Sjögren’s syndrome; UCB7665 for immune thrombocytopenia; UCB1332 for Parkinson’s disease; UCB4144/VR942 for asthma; UCB6673 for immunological diseases; UCB3491 for epilepsy; and UCB7858 for auto-inflammatory diseases. UCB SA was founded in 1928 and is headquartered in Brussels, Belgium.

Corporate Governance

UCB SA’s ISS Governance QualityScore as of August 1, 2017 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.